News
-
-
PRESS RELEASE
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Immunic presented key Vidofludimus Calcium data at the 41st Congress of ECTRIMS, highlighting its potential in multiple sclerosis. The data underscore its neuroprotective potential and promise to slow disease progression -
-
PRESS RELEASE
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
Immunic receives United States Patent Notice of Allowance for Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis, extending protection into 2041 -
-
-
-
-
-
PRESS RELEASE
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic reports positive long-term data from phase 2 EMPhASIS Trial of Vidofludimus Calcium in relapsing-remitting multiple sclerosis, showing favorable safety & tolerability profile up to 5.5 years
